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Abstract Two types of glutamyl-tRNA synthetase exist : the
discriminating enzyme (D-GluRS) forms only Glu-tRNAGlu,
while the non-discriminating one (ND-GluRS) also synthesizes
Glu-tRNAGln, a required intermediate in protein synthesis in
many organisms (but not in Escherichia coli). Testing the ca-
pacity to complement a thermosensitive E. coli gltX mutant and
to suppress an E. coli trpA49 missense mutant we examined the
properties of heterologous gltX genes. We demonstrate that
while Acidithiobacillus ferrooxidans GluRS1 and Bacillus sub-
tilis Q373R GluRS form Glu-tRNAGlu, A. ferrooxidans and
Helicobacter pylori GluRS2 form Glu-tRNAGln in E. coli in
vivo.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Faithful protein biosynthesis relies on the speci¢c amino-
acylation of cognate tRNA with the corresponding amino
acid by aminoacyl-tRNA synthetases. While many organisms
contain one synthetase for each of the 20 canonical amino
acids, the mechanism of Gln-tRNA biosynthesis di¡ers in
the three domains of life [1]. Glutaminyl-tRNA synthetase
(GlnRS) forms Gln-tRNA in eukaryotes and certain bacteria.
However, all known archaea, most bacteria and some eukary-
otic organelles lack GlnRS [1,2]. In these cases Gln-tRNA is
generated in a two-step pathway. A non-discriminating glu-
tamyl-tRNA synthetase forms Glu-tRNAGln which is con-
verted to the cognate Gln-tRNAGln by a tRNA-dependent
Glu-tRNAGln amidotransferase (Glu-AdT). Bacillus subtilis
is the best-studied example among organisms utilizing the
transamidation pathway for Gln-tRNAGln synthesis. A single
ND-GluRS, a heterotrimeric Glu-AdT, and the absence of a
gene encoding GlnRS characterize B. subtilis in this regard
[3,4].
Analysis of bacterial genomes reveals that Escherichia coli
(with a discriminating GluRS and a GlnRS) and B. subtilis
(with a single ND-GluRS and Glu-AdT) possess the ‘proto-
types’ of the machinery forming Glu-tRNA and Gln-tRNA.
However, duplicated GluRS enzymes are found in many or-
ganisms including Acidithiobacillus ferrooxidans and Helico-
bacter pylori [5,6]. To shed further light on the nature of
GluRS enzymes, we set out to develop an E. coli in vivo
system for this purpose. Based on the availability of charac-
terized missense suppression systems [7], and on the capability
of E. coli to tolerate in vivo mischarged Asp-tRNAAsn [8], we
reasoned that Glu-tRNAGln may also be tolerated. We studied
(i) a tryptophan synthetase-based E. coli genetic system [9]
and (ii) a thermosensitive E. coli gltX mutant [10] to assess
the formation of Glu-tRNAGln and Glu-tRNAGlu respectively
by transformation with heterologous gltX genes from A. fer-
rooxidans, H. pylori and B. subtilis.
2. Materials and methods
2.1. Plasmids and strains
GluRS1 and GluRS2 genes from A. ferrooxidans ATCC23270 as
well as the H. pylori 26695 GluRS2 gene were polymerase chain re-
action (PCR) ampli¢ed and cloned into the EcoRI site of the pGEX2t
(Amersham Pharmacia Biotech) expression vector. B. subtilis Q373R
and E. coli gltX were cloned in the NdeI/BglII sites of pCBS1 [8]. E.
coli trpA wild-type and trpA49 variants were cloned in the PstI/Bam-
HI restriction sites of the pMLC210 vector [11] after PCR ampli¢ca-
tion, generating the corresponding pMLCtrpA49 variants. TrpA49
carrying either the CAG or CAA glutamine codon at position 49
and B. subtilis gltX with the Q373R replacement were constructed
by PCR mutagenesis [12] using the following mutagenic primers: 5P-
CTGACGCGCTGCAGTTAGGTAC, 5P-GATACCTAACTGCAG-
CGCGTCAG, 5P-CTGACGCGCTGCAATTAGGTAC, 5P-GATAC-
CTAATTGCAGCGCGTCG, 5P-GTATCATGAGCGATTAAGCT-
ACGG, and 5P-CCGATGCTTAATCGCTCATGATACG (under-
lined are indicated the mutated codons). Because of the di¡erent ori-
gin of replication, plasmids derived from pGEX2t and pCBS1 are
compatible with pMLC210 derivatives. Plasmids were speci¢cally se-
lected by resistance to ampicillin or chloramphenicol respectively. E.
coli DH5K or JM109 were used for cloning experiments. E. coli
JP1449 [10] carrying a thermosensitive mutation in gltX (encoding
the GluRS) was used in complementation assays with heterologous
gltX. E. coli strain KS463 (E. coli Genetic Stock Center #5644) carry-
ing a trpA33 [13] inactivating mutation was used as recipient in the
missense suppression tests. E. coli A2/A2 was used for the synthesis of
indole 3-glycerol phosphate (IGP), the substrate for tryptophan syn-
thetase assay [14]. All DNA constructs and mutagenesis were con-
¢rmed by DNA sequencing.
2.2. Restoration of the thermostable phenotype of E. coli gltX strain
E. coli JP1449 was transformed with each of the plasmids contain-
ing heterologous gltX genes from the sources described above. Ampi-
cillin-resistant colonies obtained at 30‡C on Luria^Bertani (LB) agar
plates were streaked on a new plate and incubated at 42‡C. Plates
were scored every 12 h.
2.3. Suppression of E. coli trpA49 missense mutations
E. coli strain KS463 carries the inactivating mutation trpA33 [13]
which results in tryptophan auxotrophy. Cells were co-transformed
by electroporation with one of the variants of plasmid pMLCtrpA49
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carrying either glutamate (GAA) or glutamine (CAA or CAG) codons
at position 49, and plasmids carrying heterologous gltX genes. Trans-
formants were plated on LB agar with both ampicillin and chloram-
phenicol and incubated for 16 h at 37‡C. Colonies were transferred to
3 ml of LB liquid medium in the presence of antibiotics and cultured
for 16 h at 37‡C. Subsequently, cells were washed with M9 minimal
medium and streaked onto M9 minimal agar plates supplemented
with 19 amino acids (20 Wg/ml) without tryptophan. Plates were in-
cubated for 3^4 days at 30‡C and growth was scored every 12 h.
2.4. Tryptophan synthetase assay
Overnight cultures of E. coli KS463 in M9 medium with or without
tryptophan were inoculated on 400 ml of M9 as before. All cultures
were incubated at 30‡C to late log phase, harvested by centrifugation,
washed twice with NaCl (0.9%), and resuspended in bu¡er A (0.05 M
potassium phosphate (pH 7.0), 0.1 mg/ml of pyridoxal-5-phosphate,
10 mM 2-mercaptoethanol). Cell extract was prepared [14], dialyzed
against bu¡er A containing 50% glycerol and stored at 320‡C. IGP
was freshly prepared as described [8]. Tryptophan synthetase was
assayed in the IGP to Trp conversion with [3H]serine (28.0 Ci/
mmol) [15]. Enzymatic unit is de¢ned as the amount producing
1 Wmol of tryptophan/mg of protein.
3. Results
3.1. Formation of Glu-tRNAGlu by heterologous GluRS
For this analysis we chose three heterologous gltX genes
from A. ferrooxidans and H. pylori. A. ferrooxidans GluRS1
is known to glutamylate tRNAGlu and the tRNAGlnCUG isoac-
ceptor, while GluRS2 preferentially acylates tRNAGlnUUG [6].
The H. pylori GluRS2 is the special GluRS which recognizes
only tRNAGln [5,6]. Recombinant plasmids carrying A. fer-
rooxidans gltX1, gltX2 or H. pylori gltX2 were transformed
into E. coli strain JP1449. Cells transformed with recombinant
plasmids proliferated normally at the permissive temperature
(30‡C) indicating that, in the presence of functional endoge-
nous GluRS, the cloned genes were not toxic to E. coli (Fig.
1). At the non-permissive temperature (42‡C) while A. fer-
rooxidans gltX1 rescued the mutation in a similar way as
did the homologous E. coli gltX, neither A. ferrooxidans
gltX2 nor H. pylori gltX2 supported growth (Fig. 1). These
results show that gltX1, but not gltX2, encodes a GluRS that
generates E. coli Glu-tRNAGlu in vivo.
3.2. Glu-tRNAGln is formed in vivo in E. coli
To demonstrate the in vivo formation of E. coli Glu-
tRNAGln, we functionally replaced the inactive trpA33 gene
in the tryptophan auxotrophic strain E. coli KS463 by co-
transformation of the cells with recombinant plasmids carry-
ing trpA49 either with glutamate (GAG) or glutamine (CAA
or CAG) codons at position 49 of the TrpA protein. The
formation of Glu-tRNAGln by the heterologous GluRS en-
zymes should lead to glutamate incorporation at the gluta-
mine codon at position 49 of trpA restoring tryptophan syn-
thetase activity, and thus prototrophy of cells. As shown in
Fig. 2, A. ferrooxidans and H. pylori gltX2 supported growth
of the cells in the absence of tryptophan when trpA49CAA
variant was used. Neither A. ferrooxidans gltX1 nor E. coli
gltX were able to suppress the mutation. None of the heter-
ologous gltX restored prototrophy to tryptophan of
trpA49CAG variant (data not shown). All transformed cells
grew normally in the presence of tryptophan (data not
shown). This implies that A. ferrooxidans and H. pylori
gltX2 encode GluRS enzymes that charge E. coli tRNAGlnUUG
species.
To con¢rm that restoration of prototrophy was due to the
recovery of functional tryptophan synthetase, its enzymatic
activity was measured in cells co-transformed with trpA49CAA
and A. ferrooxidans gltX2 and compared to that from cells
transformed with trpAþ (Table 1). An eight-fold increase in
the enzymatic activity was observed in sample cells compared
to negative control (Table 1). The missense suppressed tryp-
tophan synthetase activity was about 10% the activity of the
wild-type control.
3.3. A single mutation makes B. subtilis gltX in vivo expression
acceptable to E. coli
B. subtilis GluRS is a standard non-discriminating enzyme
[3] and shown to glutamylate in vitro E. coli tRNAGlu and the
E. coli tRNAGlnUUG [3]. The inability to overexpress B. subtilis
GluRS in E. coli has been explained by the mischarging of this
E. coli tRNAGln species [16].
Fig. 1. Complementation of the E. coli gltXts strain JP1449 by het-
erologous gltX genes. Af1, A. ferrooxidans gltX1 ; Af2, A. ferrooxi-
dans gltX2 ; Ec, E. coli gltX ; Hp2, H. pylori gltX2 ; BsQR, B. subti-
lis gltX (Q373R); pB, pCBS1; pG, pGEX2t grown at 30 or at
42‡C.
Fig. 2. Missense suppression of E. coli trpA49CAA by heterologous
gltX genes. E. coli strain KS463 was co-transformed with pML-
CtrpA49CAA and A. ferrooxidans gltX1 (Af1), A. ferrooxidans gltX2
(Af2), E. coli gltX (Ec), H. pylori gltX2 (Hp2), B. subtilis gltX
Q373R (BsQR) or pGEX2t (pG). WT/pG, cells co-transformed with
pMLCtrpA49þ and pGEX2t.
Table 1
Recovery of tryptophan synthetase activity in cell extracts of E. coli
KS463
Af2/trpA49CAA none/trpAþ
Activitya 1.50U 0.25 15.7U 2.54
Tryptophan synthetase activity of extracts from KS463 cells co-
transformed with trpA49CAA and A. ferrooxidans gltX2 (Af2) and
trpAþ with empty vector (none) grown at 30‡C. The tryptophan syn-
thetase activity (0.187U 0.05) from cells co-transformed with E. coli
gltX and trpA49CAA grown with 0.01% tryptophan was subtracted
from the values above.
aUnits/mg protein.
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More recently it was shown that a single amino acid
change, R358Q, in Thermus thermophilus D-GluRS allowed
in vitro charging of E. coli tRNAGlu containing a glutamine
(CUG) anticodon [17]. Therefore we replaced the glutamine
present in the corresponding position in B. subtilis GluRS
with arginine to generate GluRS Q373R. The mutant B. sub-
tilis gltX gene successfully rescued the thermosensitive GluRS
mutation and allowed growth of E. coli gltX strain JP1449 at
the non-permissive temperature (Fig. 1). Thus, E. coli Glu-
tRNAGlu is generated by the mutant B. subtilis GluRS in
vivo. However, the mutant B. subtilis gltX gene did not cause
missense suppression of neither the E. coli trpA49CAA nor
trpACAG mutations, indicating that the mutant B. subtilis
GluRS Q373R does not form Glu-tRNAGln.
Together, these results indicate that the Q373R replacement
in B. subtilis GluRS restricted its tRNA speci¢city and elim-
inated charging of E. coli tRNAGlnUUG in vivo.
4. Discussion
Missense suppression, the insertion of an incorrect amino
acid for a certain codon, has been known for a long time [21],
and work with the trpA system stimulated much molecular
biology research (see e.g. [9]). As in a previous report for
Asp/Asn [8], we have developed a system for the incorpora-
tion of glutamate in response to a glutamine (CAA) codon
using mischarged Glu-tRNAGln to generate wild-type trypto-
phan synthetase K-chain in a strain that is dependent on this
enzyme for tryptophan synthesis. The required synthesis of an
essential protein is the selective force that in this case leads to
misincorporation of a canonical amino acid, and presumably
forces the elongation factor EF-Tu to carry mischarged tRNA
to the ribosome. Since this assumption is not in line with the
current view of EF-Tu speci¢city [18^20], one may use this
trpA system to probe the following questions: Will the ratio
of EF-Tu and mischarged tRNA a¡ect misincorporation?
Compared to di¡erent amino acid pairs, do proteins tolerate
more readily Glu/Gln exchanges as their physical size is sim-
ilar (despite great functional di¡erence)? Will the presence in
E. coli of Glu-AdT ‘detoxify’ the trpA mischarging system?
What are the molecular determinants that make a GluRS
recognize tRNAGln ? The trpA system will allow future studies
to address these exciting questions.
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